226396-62-9Relevant articles and documents
CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPY
-
Paragraph 0066; 00115, (2020/01/24)
Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase ("MMP") inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In parti
Synthesis and structure-activity relationships of β- and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy
Becker, Daniel P.,Villamil, Clara I.,Barta, Thomas E.,Bedell, Louis J.,Boehm, Terri L.,DeCrescenzo, Gary A.,Freskos, John N.,Getman, Daniel P.,Hockerman, Susan,Heintz, Robert,Howard, Susan Carol,Li, Madeleine H.,McDonald, Joseph J.,Carron, Chris P.,Funckes-Shippy, Chris L.,Mehta, Pramod P.,Munie, Grace E.,Swearingen, Craig A.
, p. 6713 - 6730 (2007/10/03)
α-Piperidine-β-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the β-sulfones subsequently led to the discovery of hitherto unknown α-sulfone h